Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open-label, Controlled Clinical Study Comparing Toripalimab Adjuvant Therapy Versus Clinical Observation in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)

NCT06903871 is registered in ClinicalTrials.gov with Hebei Medical University Fourth Hospital as lead sponsor.

NCT NCT06903871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06903871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open-label, Controlled Clinical Study Comparing Toripalimab Adjuvant Therapy Versus Clinical Observation in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
Lead sponsor
Hebei Medical University Fourth Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 1, 2025
Completion date
March 1, 2030
Enrollment
190 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma stage ii, esophageal squamous cell carcinoma stage iii